Assets
| Type | Time | Amount | Unit |
|---|---|---|---|
| ifrs-full:Assets | 2023-12-31 | 89811000 | dkk |
| ifrs-full:Assets | 2022-12-31 | 108640000 | dkk |
Revenue
| Type | Start date | End date | Amount | Unit |
|---|---|---|---|---|
| ifrs-full:Revenue | 2023-01-01 | 2023-12-31 | 30958000 | dkk |
| ifrs-full:Revenue | 2022-01-01 | 2022-12-31 | 28969000 | dkk |
XML
See the xml submitted here:
XML: INVALID
Separator
The full data:
<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance"
xmlns="http://www.w3.org/1999/xhtml"
xmlns:arr="http://xbrl.dcca.dk/arr"
xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12"
xmlns:cmn="http://xbrl.dcca.dk/cmn"
xmlns:sob="http://xbrl.dcca.dk/sob"
xmlns:link="http://www.xbrl.org/2003/linkbase"
xmlns:BIO="http://xbrl.bioporto.com/2023-12-31"
xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full"
xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
xmlns:ix="http://www.xbrl.org/2013/inlineXBRL"
xmlns:mrv="http://xbrl.dcca.dk/mrv"
xmlns:fsa="http://xbrl.dcca.dk/fsa"
xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
xmlns:gsd="http://xbrl.dcca.dk/gsd"
xmlns:xlink="http://www.w3.org/1999/xlink"
id="DKGAAP"
xml:lang="en">
<link:schemaRef xlink:href="http://archprod.service.eogs.dk/taxonomy/20221001/entryDanishGAAPExcludingBalanceSheetIncomeStatementIncludingManagementsReview20221001.xsd"
xlink:type="simple"/>
<xbrli:context id="ctx-1">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-2">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="ctx-32">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-33">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
<cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-34">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-35">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>3</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-36">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>4</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-37">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
<cmn:memberOfBoardIdentifier>5</cmn:memberOfBoardIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-38">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
<cmn:auditorIdentifier>1</cmn:auditorIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:context id="ctx-39">
<xbrli:entity>
<xbrli:identifier scheme="http://standards.iso.org/iso/17442">5299004SWFL5JAN4W830</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2023-01-01</xbrli:startDate>
<xbrli:endDate>2023-12-31</xbrli:endDate>
</xbrli:period>
<xbrli:scenario>
<xbrldi:explicitMember dimension="cmn:ConsolidatedSoloDimension">cmn:ConsolidatedMember</xbrldi:explicitMember>
<xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
<cmn:auditorIdentifier>2</cmn:auditorIdentifier>
</xbrldi:typedMember>
</xbrli:scenario>
</xbrli:context>
<xbrli:unit id="pure">
<xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit>
<mrv:CorporateGovernanceReport contextRef="ctx-1" id="pp-value-1-1" xml:lang="en">Governance Corporate Governance BioPorto remains focused on good corporate governance, having implemented all, except for four recommendations from the Committee of Corporate Governance (Komitéen for god selskabsledelse) for companies listed on the Nasdaq Copenhagen Stock Exchange. The Board of Directors believes that the Company operates in compliance with guidelines and recommendations that support the Companyâs business model and can create value for BioPortoâs stakeholders. Regularly and at least once a year, the Board of Directors monitors adherence to the recommendations on corporate governance in order to ensure appropriate utilization of and compliance with the recommendations and legislation. In accordance with Section 107 b of the Danish Financial Statements Act, BioPorto has published a statutory report on Corporate Governance for the financial year 2023 on the Companyâs website. The Board of Directors BioPorto is managed in a two-tier structure composed of the Board of Directors and the Executive Management. The General Meeting elects between three and seven members to the Board of Directors, which currently consists of five members. The Board of Directors elects a chairperson and a vice chairperson. Members hold office for terms of one year at a time and may be re-elected. Members of the Board are nominated and stand for election based on their specific qualifications and experience relevant to BioPorto. The Board of Directors is composed to provide a combination of relevant industry experience and functional experience. Not all current Board members are considered independent persons, but the Board of Directors can act independently. Each Board memberâs qualifications are listed on the Companyâs website: https://bioporto.com/about-bioporto/. The Board is responsible for the overall strategic management and the financial and managerial supervision of BioPorto, and regular evaluation of Executive Management. The Board of Directors also ensures that the Company is properly managed as required by the Articles of Association, other guidelines, policies and applicable rules and regulations. Furthermore, the Board of Directors makes decisions on all unusual matters or matters with far-reaching implications. The Board of Directors defines guidelines for the distribution of responsibilities between the Board of Directors and the Executive Management but does not participate in the day-to-day management of the Company. The duties of the Board of Directors are described in the Rules of Procedure. The Executive Management is appointed by the Board of Directors, which lays down their terms and conditions of employment and the framework for their duties. The Executive Management is responsible for the day-to-day management of the Company in compliance with the guidelines and directions issued by the Board. The day-to-day operations do not include transactions of an unusual nature or of material importance to the affairs of the Company. As of 31 December 2023, and on the date of the Annual Report, the Board of Directors consists of five board members, of which four are male and one is female. As of the date of this Annual Report, the Executive Management consists of Peter Mørch Eriksen, CEO, who took on the role as CEO in January 2024, due to termination of the former CEO. Peter Mørch Eriksen was the CEO of BioPorto prior to Anthony Pare and has the requisite knowledge and experience to execute his duties in a competent manner. A total of 20 Board meetings were held in 2023: 11 Board meetings were originally planned for in 2023 according to the Boards Annual Schedule and additionally 9 meetings were held following up on the FDA Process and other Company related matters, issuing Warrants, and adopting a capital increase. 11 meetings are initially planned for 2024 in accordance with the Board of Directorsâ annual schedule, which can be altered at any time to allow for additional meetings, if deemed necessary. Number of meetings attended by each Board member Nomination & out of the total number of meetings during 2023: Remuneration Board of Directors Committee Audit Committee Christopher Lindop (Resigned on 27 April 2023) 9/20 John McDonough 20/20 1/1 4/4 Don Hardison 19/20 1/1 Michael Singer 19/20 4/4 Jan Leth Christensen (resigned on 4 December 2023) 19/20 1/1 Peter Mørch Eriksen 20/20 Ninfa Saunders (Elected on 27 April 2023) 11/20 4/4 Board committees To support the Board in its duties, the Board has established and appointed the following subcommittees and respective members that are charged with reviewing issues pertaining to their respective fields that are due to be considered at board meetings: ⢠Nomination & Remuneration Committee: Don Hardison*, John McDonough, Peter Mørch Eriksen**⢠Audit Committee: Ninfa Saunders*, John McDonough and Michael Singer. Mr. McDonough possesses the necessary professional qualifications and experience.* indicates the independent chair of each committee, ** indicates if the committee member is considered non-independent,More information about the committees, including the terms of reference that specify their tasks and responsibilities, are available on the Companyâs website. Evaluation of the performance of the Board of Directors and the Executive Management Annually, the Board of Directors conducts a self-evaluation of the Board's accomplishments and composition. The Chair heads the annual evaluation, which at least every third year is conducted by an external consultant. The process, whether it is facilitated internally or by external consultants, evaluates topics such as board dynamics, board agenda, quality of the material that is submitted to the Board, discussions at the Board meetings, the chairâs leadership of the Board, strategy, Board composition and Board competencies. Typically, the process is further facilitated by each Board member completing a detailed questionnaire, and the Board members are asked to score to which extent they agree to the individual questions. The results of the questionnaire are then discussed at a subsequent Board meeting, and the individual comments submitted are used in the planning and handling of future Board meetings. The 2023 self-evaluation was conducted externally, and the key conclusions were positive with continued satisfaction with the Boardâs work as well as the work in the committees. Strategic planning and continued optimization of Board meeting efficiency will be focus areas in 2024. Remuneration policy and report The remuneration of the Board and the Executive Management is governed by the Companyâs Remuneration Policy which was updated in 2023 and subsequently approved by the shareholders at the Annual General Meeting in 2023. In accordance with section 139b in the Danish Companies Act, BioPorto has prepared a Remuneration Report on the remuneration of the individual members of the Board and the Executive Management in 2023. Business Ethics The Company has established a Code of Conduct that is made available to external stakeholders via the Companyâs website. Likewise, the Company has established a whistleblower scheme that is available to all employees in the BioPorto Group. Tax Policy The Board has adopted a Tax Policy describing the Companyâs governing principles by which the Company manages its tax affairs. The policy is located on the Companyâs website: www.bioporto.com/governance. </mrv:CorporateGovernanceReport>
<mrv:StatementOfPolicyForDataEthics contextRef="ctx-1" id="pp-value-3-1" xml:lang="en">Data Ethics In 2023, the Company continued its initiatives to support our continued commitment to maintain strong data ethics. As part of the annual cycle, internal procedures were reviewed and improved, and data protection awareness training activities were carried out for relevant employees. The Board of Directors has adopted a policy on data ethics that is available on the Companyâs website: www. bioporto.com/governance: https://bioporto.com/wp-content/uploads/2022/04/2022-Data-Ethics-Policy.pdf </mrv:StatementOfPolicyForDataEthics>
<mrv:StatementOfCorporateSocialResponsibility contextRef="ctx-1" id="pp-value-4-1" xml:lang="en">Privacy and GDPR (G) BioPorto focuses on privacy and protection of personal data throughout the Company, covering the data of employees, partners, and other stakeholders. BioPorto has implemented strong measures to protect personal data and comply with the EU General Data Protection Regulation (GDPR) and national personal data protection legislation. BioPorto implemented a Data Ethics Policy. All new employees received GDPR and data training as part of their introductory program in 2023. In 2024, BioPorto will continue securing its compliance with the above-mentioned policies, and new employees receive GDPR and data training. Corporate Social Responsibility, cf. Section 99a and 99b of the Danish Financial Statements Act UN Global Compact BioPorto is aware of its social responsibility and endeavors to improve its social and environmental conditions. BioPorto adheres to the 10 principles provided by the UN Global Compact, and the latest Communication on Progress, which is available on the Companyâs website. In several areas, BioPorto fulfills its responsibility solely by complying with current law, but in other areas, the Companyâs responsibility has been expanded to include preventive activities for optimizing various conditions. It is important to BioPorto to highlight these efforts vis-Ã -vis its customers, suppliers, shareholders, other stakeholders, etc., to ensure that the outside world can have confidence in the Company to live up to its social responsibility. Therefore, BioPorto continues its participation in the Global Compact, which identifies ten principles for social commitment as defined by the UN constitute a global frame of reference and are enumerated with commentary, below. At the same time, through the Groupâs commitment, it will try to encourage the parties with whom it interacts to consider and shoulder their share of these responsibilities. Human rights 1. Businesses should support and respect the protection of internationally proclaimed human rights; and 2. make sure that they are not complicit in human rights abuses. BioPorto supports and respects internationally recognized human rights. It is imperative for BioPorto to comply with international human rights and labor standards and to work against discrimination. BioPorto is against any form of discrimination and strives to treat all employees and potential applicants equally, regardless of sex, age, ethnicity, disability, attitudes, religion, interests, life philosophy, and personal interests. BioPortoâs compliance in this area is widely covered by its Code of Conduct as well as observance of the national labor and anti-discrimination laws in the countries in which it operates. BioPortoâs employees are bound by the Code of Conduct, and the Company is implementing the Code of Conduct into supplier contracts to ensure that the Companyâs suppliers respect human rights. In their introductory program, BioPortoâs employees are trained on human rights and the Code of Conduct. Employees are also trained via the Companyâs QMS System. Central to BioPorto's approach is the implementation of a whistleblower scheme in 2023, providing employees with a confidential avenue to report any concerns regarding human rights violations or unethical behavior. This scheme underscores the company's commitment to transparency and accountability, ensuring that all issues are promptly addressed. BioPorto also conducts clinical trials in a manner that recognizes the importance of respecting research participants while protecting their safety. It does this by applying the highest legal, ethical, and scientific standards, in addition to complying with applicable laws and regulations. BioPortoâs executive management team monitors and evaluates performance annually. Any alleged incidents of human rights abuse will be reported to executive management, who will take prompt action. Zero incidents of human rights violations were reported in 2023. In 2024, BioPorto will continue the same focus as in 2023 through the work performed in the Companyâs Work Environment Group. By prioritizing the well-being and rights of its employees, the company demonstrates its dedication to corporate responsibility and ethical leadership. Looking ahead to 2024, BioPorto remains unwavering in its commitment to upholding human rights. The Work Environment Group at the Danish enterprise will continue its diligent efforts to enforce policies that promote a safe, inclusive, and equitable workplace environment. Labor rights 3. Businesses should uphold the freedom of association and the effective recognition of the right to collective bargaining; 4. the elimination of all forms of forced and compulsory labor; 5. the effective abolition of child labor; and 6. the elimination of discrimination in respect of employment and occupation. Danish and American traditions, culture and laws mean that labor rights are naturally supported and complied with by BioPorto, both in Denmark and the United States. BioPorto has no external suppliers in countries that are known for the use of child labor or forced and compulsory labor, and BioPorto deems that there is a very low risk of this taking place in areas where BioPorto might be expected to operate. BioPorto has established a Code of Conduct covering the above. BioPorto employees are bound by this Code of Conduct, and the Company is continuously implementing the Code of Conduct into supplier contracts to ensure that suppliers comply with these labor rights. BioPorto actively supports and respects human rights and labor standards, and it provides a safe and healthy working environment for its staff that includes opportunities for professional and personal development. The BioPorto group has fair and equal employment terms and working conditions, including equality and non-discrimination. BioPortoâs employee handbook covers policies concerning employee rights. BioPorto considers employee safety and health to be among its highest priorities and consistently work to maintain a safe and healthy work environment with procedures in placeto mitigate risks and promote well-being. Both physical and mental aspects of the work environment are diligently monitored and refined by the Work Environment Group and the Management Team to minimize the likelihood of accidents, injuries, or illnesses. Comprehensive training programs conducted on site and through external training equip employees with the necessary skills to handle hazardous materials and chemicals safely. In the event of any breaches of labor standards, BioPorto has established reporting channels where such concerns can be escalated to executive management for thorough investigation and resolution. By maintaining a commitment to compliance and continual improvement, BioPorto strives to foster a work environment where every employee feels valued, protected, and empowered. BioPorto monitors and evaluates performance yearly by looking at work related injuries, employee related cases with a union. During 2023 BioPorto had zero employee-related cases with unions and zero work related injuries otherwise recognized and reported through the Work Environment Group, the Whistleblower Hotline and the management teamsâ day to day engagement with the work force. The implementation of the Whistleblower Hotline in 2023 at BioPorto has not only empowered employees but also facilitated improved internal reporting procedures, covering a wide range of issues such as sexual harassment, bullying, discrimination, and physical violence. With this initiative BioPorto effectively encouraged transparency and accountability within the organization; Zero incidents have been reported in 2023,. In 2024, BioPorto will continue efforts on ensuring that suppliers adhere to relevant standards, including its Code of Conduct, and will aim to maintain or improve a balanced diversity, including for both genders. In the composition of its staff, BioPorto endeavors to achieve an equal gender breakdown as well as a diversity of educational backgrounds, nationalities and cultures. This diversity provides a dynamic work environment and encourages collaboration to the benefit of staff and Company efforts alike. For further information, please see the below section on diversity. Environment 7. Businesses should support a precautionary approach to environmental challenges; 8. undertake initiatives to promote greater environmental responsibility; and 9. encourage the development and diffusion of environmentally friendly technologies. BioPortoâs in-house production is limited in scope and of such a nature that it has an insignificant environmental impact and related risk. BioPorto is committed to full compliance with all environmental laws, standards, and guidelines in the jurisdictions where it operates and continuously seeks to reduce its environmental impact as much as possible. An ongoing effort will be made in an environmentally conscious way to minimize any other possible environmental impact, including the consumption of water and electricity, which will cut costs at the same time. BioPortoâs activities are primarily knowledge-based, and employees are encouraged to be mindful of the environment and climate, and to produce as little waste as possible. Employees are bound by BioPortoâs Code of Conduct and trained in the Companyâs QMS System and the Company is implementing the Code of Conduct into supplier contracts. BioPorto continues to consume less paper by encouraging electronic copies, double-sided printing when hard copies are necessary, and release of print app. Furthermore, recycling and proper disposal of ink and toner cartridge from the printers has been installed. BioPorto has made another conscious choice to exchange cleaning equipment such as cloths and soap dispensers to more sustainable items reducing microplastic waste. At the Hellerup office environment BioPorto has installed an enhanced system for recycling and separation of waste, as well as exchanging the coffee machine to a one-cup-at the time, reducing water waste. Management will continually encourage employees to embrace environmental and climate friendly initiatives. In 2024, BioPorto will continue working to minimize environmental impact Any environmental incident would be reported to the executive management team, and they would take prompt action to make sure the incident would not happen again. In 2023 BioPorto has adopted a Whistle-blower Scheme, which covers significant infringements of environmental regulations and pollution of the environment. Zero incidents have been reported in 2023. Anti-corruption 10. Businesses should work against corruption in all its forms, including extortion and bribery. BioPorto has a zero-tolerance policy regarding corruption, bribery, and similar methods. BioPortoâs activities must follow the required country anti-corruption legislation and the UN Convention against Corruption. Corruption problems have not historically affected BioPortoâs activities, and BioPorto has not been involved in any legal cases, rulings or other events related to corruption and bribery. BioPortoâs Code of Conduct covers the above. Employees are bound by BioPortoâs Code of Conduct and the Company implements the Code of Conduct into supplier contracts. BioPorto does not permit or participate in money laundering. All new employees receive training as part of their introductory program regarding anti-corruption and the Code of Conduct. Any incidents of corruption will be reported to executive management, and they will take prompt action to ensure that a similar incident will not happen again. In 2023 BioPorto has adopted a Whistle-blower Scheme, which covers bribery or corruption. Zero incidents have been reported in 2023. Risks The Groupâs risk of affecting the environment and climate, human rights, and anti-corruption is assessed to be limited. The risk assessment has been carried out in such a way that selected topics have been analyzed for their potential risk for BioPorto and the Groupâs stakeholders, respectively. In this context, risk is a product of the subjectâs proportional role in the daily business, and the probability of the negative impact each topic may have on the Group or its stakeholders. To the extent that risks have been identified, the individual areas are described below, together with the related policies. For a detailed description of BioPortoâs additional business risks, see the Risk management section of this Annual Report. </mrv:StatementOfCorporateSocialResponsibility>
<mrv:StatementOfTheDiversityPolicies contextRef="ctx-1" id="pp-value-8-1" xml:lang="en">Diversity BioPortoâ s Diversity Policy In pursuit of fostering an inclusive and equitable workplace environment, BioPortoâs commitment to diversity remains steadfast as we take off on the journey of 2024. Grounded in our core values of equality, respect, and integrityand to support our continued work regarding diversity in 2024 BioPortoâs Board of Directors has adopted the following Policy: âBioPorto is committed to continue working towards ensuring and furthering equal opportunities for all employees in respect of differences, such as gender, age, religion, sexual orientation and ethnicity, as all â in our view â serve as key components in ensuring a better, more dynamic and healthier business. We believe that employees should be recognized because of â and not despite â their diversity. The view extended through this policy also includes maintaining equal opportunities for women and men at all management levels in the BioPorto group. The Board of Directors annually discusses the Companyâs activities to ensure relevant diversity at management levels and evaluates the policy on diversity.â Central to our commitment is the principle that all employees should be valued and recognized for their unique perspectives, talents, and contributions. We reject the notion of "fitting in" and instead champion a culture where every voice is heard, every perspective is respected, and every individual is empowered to thrive. As part of our ongoing efforts, BioPorto's Board of Directors diligently reviews and evaluates our diversity initiatives annually, reaffirming our dedication to fostering an inclusive workplace where diversity is not just a goal but a lived reality. </mrv:StatementOfTheDiversityPolicies>
<mrv:StatementOfTargetFiguresAndPoliciesForTheUnderrepresentedGender contextRef="ctx-2" id="pp-value-9-1" xml:lang="en">Diversity in the BioPorto Group In 2023, the diversity landscape among our entire workforce continued to evolve positively. The proportion of female employees increased to 61%, reflecting a growing gender balance within our organization. Additionally, the representation of non-Danish employees remained steady at 61%, underscoring our commitment to embracing cultural diversity. 2023 BioPorto Group Female Male Non-Danish All Employees (29 persons) 61% 39% 61% Management (6 persons) 33% 67% 50% Executive Management (1 person) 0% 100% 100% BioPorto A/S - Board of Directors (5 persons) 20% 80% 80% BioPorto Diagnostics A/S - Board of Directors (3 persons) 0% 100% 33% BioPorto Inc. - Board of Directors (5 persons) 20% 80% 100% BioPorto Diagnostics Inc. - Board of Directors (2 persons) 50% 50% 100% As we mark the progress made in advancing diversity and inclusion within our organization, we recognize that our journey is ongoing. We remain steadfast in our commitment to creating a workplace where individuals from diverse backgrounds thrive, contribute meaningfully, and collectively drive our shared success. </mrv:StatementOfTargetFiguresAndPoliciesForTheUnderrepresentedGender>
<mrv:InformationOnEqualDistributionOfWomenAndMenBoardOfDirectors contextRef="ctx-2" id="pp-value-11-1" xml:lang="en">Diversity in the Board of Directors of BioPorto A/S Diversity in the composition of the Board is sought, with a reasonable age composition, several nationalities, and an equal gender ratio. The Board currently has five members, of which four are male and one is female. </mrv:InformationOnEqualDistributionOfWomenAndMenBoardOfDirectors>
<mrv:StatusOfAchievementOfTargetFigureOfUnderrepresentedGenderBoardOfDirectors contextRef="ctx-2" id="pp-value-13-1" xml:lang="en">The Companyâs Board composition underwent a transformative shift towards greater diversity in 2023. The inclusion of a female board member increased our gender diversity, marking a substantial improvement from the previous year. This first milestone underscores our commitment to promoting gender equality and have a 40/60 balance by 2027. Moreover, the representation of non-Danish board members surged to 80%, reflecting our dedication to embracing global perspectives and insights in governance and strategic direction ensuring diverse perspectives at the highest levels of decision-making. The Companyâs prior target was defined to reach a 40% target in 2026 but was revised due to the need to attract the right candidates. As of 31 December 2023, and as of the date of this Annual Report the following information applies to the Board of Directors. Board of Directors 2023 2024 2025 2026 2027 Number of Board Members 5 Underrepresented gender in % 20% Target date 2027 Target number in % 40 % </mrv:StatusOfAchievementOfTargetFigureOfUnderrepresentedGenderBoardOfDirectors>
<mrv:PrimaryActionsForFulfillmentOfTargetFigureOfUnderrepresentedGenderBoardOfDirectors contextRef="ctx-2" id="pp-value-14-1" xml:lang="en">The Nomination & Remuneration Committee has a policy for evaluating candidates of both genders for vacant Board positions. For future vacant Board positions, the Nomination & Remuneration committee will continue to evaluate candidates of both genders. </mrv:PrimaryActionsForFulfillmentOfTargetFigureOfUnderrepresentedGenderBoardOfDirectors>
<mrv:InformationOnExemptFromProvidingInformationOnTargetFiguresOfUnderrepresentedGenderForOtherManagementLevelsDueToTheNumberOfEmployees contextRef="ctx-2" id="pp-value-15-1" xml:lang="en">Executive Management and other layers of the Management of BioPorto A/S The Company has not set a target for the unrepresented gender in the Executive Management and other layers of the Management, as the Companyâs size is below the minimum thresholds of 50 employees or more cf. guidelines from the Danish Business Authority, section 4.1.2. The Company has adopted a general Diversity Policy cf. above, but the Company is below the threshold of 50 employees or more cf. guidelines from the Danish Business Authority, section 4.2 and accordingly not obligated to adopt a Policy. As of 31 December 2023, and as of the date of this Annual Report the following information applies to the Executive Management and other layers of the Management. Executive Management & Other 2023 2024 2025 2026 2027 Layers of the Management Number of Members 1 Underrepresented gender in % 0% Target date N/A Target number in % N/A </mrv:InformationOnExemptFromProvidingInformationOnTargetFiguresOfUnderrepresentedGenderForOtherManagementLevelsDueToTheNumberOfEmployees>
<gsd:NameOfSubmittingEnterprise contextRef="ctx-1" xml:lang="en">BioPorto A/S</gsd:NameOfSubmittingEnterprise>
<gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="ctx-1" id="pp-value-20-1" xml:lang="en">Tuborg Havnevej 15</gsd:AddressOfSubmittingEnterpriseStreetAndNumber>
<gsd:ReportingPeriodNumber contextRef="ctx-1" decimals="0" unitRef="pure">2023</gsd:ReportingPeriodNumber>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-32" xml:lang="en">John McDonough</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<fsa:ClassOfReportingEntity contextRef="ctx-1">Reporting class D</fsa:ClassOfReportingEntity>
<cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx-33" xml:lang="en">Peter Mørch Eriksen </cmn:NameAndSurnameOfMemberOfExecutiveBoard>
<cmn:TitleOfMemberOfExecutiveBoard contextRef="ctx-33" id="pp-value-162-1" xml:lang="en">Chief Executive Officer </cmn:TitleOfMemberOfExecutiveBoard>
<gsd:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="ctx-1" id="pp-value-163-1" xml:lang="en">John McDonough </gsd:NameAndSurnameOfChairmanOfGeneralMeeting>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-34" id="pp-value-165-1" xml:lang="en">Don Hardison </cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-35" xml:lang="en">Michael Singer </cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx-32" xml:lang="en">Chairman </cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx-34" xml:lang="en">Vice Chairman </cmn:TitleOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-36" xml:lang="en">Ninfa Saunders </cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-37" xml:lang="en">Peter Mørch Eriksen </cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
<sob:StatementByExecutiveAndSupervisoryBoards contextRef="ctx-1" id="pp-value-160-1" xml:lang="en">Statement by the Board of Directors and Management The Board of Directors and Executive Management today considered and approved the Annual Report of the BioPorto Group and the Parent Company for the period January 1 to December 31, 2023. The Consolidated Financial Statements have been prepared in accordance with International Accounting Standards (IFRS) and further requirements in the Danish Financial Statements Act, and the Parent Company Financial Statements have been prepared in accordance with the Danish Financial Statements Act. In our opinion, the Consolidated Financial Statements and the Parent Company Financial Statements give a true and fair view of the financial position at December 31, 2023 of the Group and the Parent Company and of the results of the Group and Parent Company operations and consolidated cash flows for the financial year January 1 to December 31, 2023. In our opinion, Managementâs commentary includes a fair review of the development in the operations and financial circumstances of the Group and the Parent Company, of the results for the year, and of the financial position of the Group and the Parent Company in general, as well as a description of the principal risks and uncertainties pertaining to the Group and the Parent Company. In our opinion, the Annual Report of the Group and the Parent Company for the financial year January 1 to December 31, 2023, identified as 5299004SWFL5JAN4W830-2023-12-31-en.zip, has been prepared, in all material respects, in compliance with the ESEF Regulation. We recommend that the Annual Report be adopted at the Annual General Meeting. Hellerup, April 4, 2024 </sob:StatementByExecutiveAndSupervisoryBoards>
<arr:OpinionOnAuditedFinancialStatements contextRef="ctx-1" id="pp-value-170-1" xml:lang="en">Report on the consolidated financial statements and the parent financial statements Opinion We have audited the consolidated financial statements and the parent financial statements of Bioporto A/S for the financial year 1 January - 31 December 2023 , which comprise the income statement, balance sheet, statement of changes in equity and notes, including material accounting policy information, for the Group as well as the Parent, and the statement of comprehensive income and the cash ï¬ow statement of the Group. The consolidated financial statements are prepared in accordance IFRS Accounting Standards as adopted by the EU and additional requirements for listed entities in Denmark, and the Parent financial statements are prepared in accordance with the Danish Financial Statements Act. In our opinion, the consolidated financial statements give a true and fair view of the Groupâs financial position at 31 December 2023, and of the results of its operations and cash ï¬ows for the financial year 1 January - 31 December 2023 in accordance with International Financial Reporting Standards as adopted by the EU and additional requirements under the Danish Financial Statements Act. Furthermore, in our opinion, the parent financial statements give a true and fair view of the Parentâs financial position at 31 December 2023, and of the results of its operations for the financial year 1 January - 31 December 2023 in accordance with the Danish Financial Statements Act. Our opinion is consistent with our audit book comments issued to the Audit Committee and the Board of Directors. </arr:OpinionOnAuditedFinancialStatements>
<arr:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="ctx-1" id="pp-value-171-1" xml:lang="en">Basis for opinion We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditorâs responsibilities for the audit of the consolidated financial statements and the parent financial statements" section of this auditorâs report. We are independent of the Group in accordance with the International Ethics Standards Board for Accountantsâ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is suï¬cient and appropriate to provide a basis for our opinion. To the best of our knowledge and belief, we have not provided any prohibited non-audit services as referred to in Article 5(1) of Regulation (EU) No 537/2014. We were appointed auditors of Bioporto A/S for the first time on 23.11.2022 for the financial year 2022. We have been reappointed annually by decision of the general meeting for a total contiguous engagement period of 2 years up to and including the financial year 2023. </arr:DescriptionOfQualificationsOfAuditedFinancialStatements>
<arr:KeyAuditMattersAudit contextRef="ctx-1" id="pp-value-172-1" xml:lang="en">Key audit matters We have determined that there are no key audit matters to communicate in our report. </arr:KeyAuditMattersAudit>
<arr:MaterialUncertaintyConcerningGoingConcernAudit contextRef="ctx-1" id="pp-value-173-1" xml:lang="en">Material uncertainty related to going concern We draw attention to Note 22 in the consolidated financial statements, which describes that the necessary cash flow to support the planned activities is depending on both on both the completion of and the amount of cash received from the planned capital increase in 2024. Management is expecting a capital increase in 2024 but no commitments has been made. This indicates that a material uncertainty exists that may cast significant doubt on the Groupâs ability to continue as a going concern. Our opinion is not modified in respect of this matter. </arr:MaterialUncertaintyConcerningGoingConcernAudit>
<arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="ctx-1" id="pp-value-175-1" xml:lang="en">Statement on managementâs review Management is responsible for the management review. Our opinion on the consolidated financial statements and the parent financial statements does not cover the management review, and we do not express any form of assurance conclusion thereon. In connection with our audit of the consolidated financial statements and the parent financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the consolidated financial statements and the parent financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the management review provides the information required by relevant law and regulations. Based on the work we have performed, we conclude that the management review is in accordance with the Consolidated financial statements and the Parent financial statements and has been prepared in accordance with the requirements of the relevant law and regulation. We did not identify any material misstatement of the management review. </arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements>
<arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="ctx-1" id="pp-value-174-1" xml:lang="en">Managementâs responsibilities for the consolidated financial statements and parent financial statements Management is responsible for the preparation of consolidated financial statements and parent financial statements that give a true and fair view in accordance with IFRS Accounting Standards as adopted by the EU and additional requirements of the Danish Financial Statements Act as well as the preparation of parent financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of consolidated financial statements and parent financial statements that are free from material misstatement, whether due to fraud or error. In preparing the consolidated financial statements and the parent financial statements, Management is responsible for assessing the Groupâs and the Parentâs ability to continue as a going concern, for disclosing, as applicable, matters related to going concern, and for using the going concern basis of accounting in preparing the consolidated financial statements and the parent financial statements unless Management either intends to liquidate the Group or the Entity or to cease operations, or has no realistic alternative but to do so. </arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements>
<arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="ctx-1" id="pp-value-176-1" xml:lang="en">Auditorâs responsibilities for the audit of the consolidated financial statements and the parent financial statements Our objectives are to obtain reasonable assurance about whether the consolidated financial statements and the parent financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditorâs report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to inï¬uence the economic decisions of users taken on the basis of these consolidated financial statements and these parent financial statements. As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional skepticism throughout the audit. We also: ⢠Identify and assess the risks of material misstatement of the consolidated financial statements and the parent financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is suï¬cient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. ⢠Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the eï¬ectiveness of the Groupâs and the Parentâs internal control. ⢠Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management. ⢠Conclude on the appropriateness of Managementâs use of the going concern basis of accounting in preparing the consolidated financial statements and the parent financial statements, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's and the Parentâs ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditorâs report to the related disclosures in the consolidated financial statements and the parent financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditorâs report. However, future events or conditions may cause the Group and the Entity to cease to continue as a going concern. ⢠Evaluate the overall presentation, structure and content of the consolidated financial statements and the parent financial statements, including the disclosures in the notes, and whether the consolidated financial statements and the parent financial statements represent the underlying transactions and events in a manner that gives a true and fair view. ⢠Obtain suï¬cient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and, where applicable, safeguards put in place and measures taken to eliminate threats. From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements and the parent financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditorâs report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication. </arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed>
<arr:AuditorsReportOnXbrlTagging contextRef="ctx-1" id="pp-value-178-1" xml:lang="en">Report on compliance with the ESEF Regulation As part of our audit of the consolidated financial statements and the parent financial statements of Bioporto A/S we performed procedures to express an opinion on whether the annual report for the financial year 2023, with the file name , is prepared, in all material respects, in compliance with the Commission Delegated Regulation (EU) 2019/815 on the European Single Electronic Format (ESEF Regulation), which includes requirements related to the preparation of the annual report in XHTML format and iXBRL tagging of the consolidated financial statements including notes. Management is responsible for preparing an annual report that complies with the ESEF Regulation. This responsibility includes: ⢠The preparing of the annual report in XHTML format; ⢠The selection and application of appropriate iXBRL tags, including extensions to the ESEF taxonomy and the anchoring thereof to elements in the taxonomy, for financial information required to be tagged using judgement where necessary; ⢠Ensuring consistency between iXBRL tagged data and the consolidated financial statements presented in human readable format; and ⢠For such internal control as Management determines necessary to enable the preparation of an annual report that is compliant with the ESEF Regulation. Our responsibility is to obtain reasonable assurance on whether the annual report is prepared, in all material respects, in compliance with the ESEF Regulation based on the evidence we have obtained, and to issue a report that includes our opinion. The nature, timing and extent of procedures selected depend on the auditorâs judgement, including the assessment of the risks of material departures from the requirements set out in the ESEF Regulation, whether due to fraud or error. The procedures include: ⢠Testing whether the annual report is prepared in XHTML format; ⢠Obtaining an understanding of the companyâs iXBRL tagging process and of internal control over the tagging process; ⢠Evaluating the completeness of the iXBRL tagging of the consolidated financial statements including notes; ⢠Evaluating the appropriateness of the companyâs use of iXBRL elements selected from the ESEF taxonomy and the creation of extension elements where no suitable element in the ESEF taxonomy has been identified; ⢠Evaluating the use of anchoring of extension elements to elements in the ESEF taxonomy; and ⢠Reconciling the iXBRL tagged data with the audited consolidated financial statements. In our opinion, the annual report of Bioporto A/S for the financial year 2023, with the file name 5299004SWFL5JAN4W830-2023-12-31-en.zip, is prepared, in all material respects, in compliance with the ESEF Regulation. </arr:AuditorsReportOnXbrlTagging>
<arr:SignatureOfAuditorsPlace contextRef="ctx-1" xml:lang="en">Copenhagen</arr:SignatureOfAuditorsPlace>
<arr:SignatureOfAuditorsDate contextRef="ctx-1">2024-04-04</arr:SignatureOfAuditorsDate>
<cmn:NameOfAuditFirm contextRef="ctx-38" id="pp-value-184-1" xml:lang="en">Deloitte Statsautoriseret Revisionspartnerselskab </cmn:NameOfAuditFirm>
<cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx-38">33963556</cmn:IdentificationNumberCvrOfAuditFirm>
<cmn:NameAndSurnameOfAuditor contextRef="ctx-38" xml:lang="en">Niels Skannerup Vendelbo </cmn:NameAndSurnameOfAuditor>
<cmn:DescriptionOfAuditor contextRef="ctx-38" xml:lang="en">State Authorised Public Accountant </cmn:DescriptionOfAuditor>
<cmn:IdentificationNumberOfAuditor contextRef="ctx-38">mne34532</cmn:IdentificationNumberOfAuditor>
<cmn:NameAndSurnameOfAuditor contextRef="ctx-39" xml:lang="en">Lars Hansen </cmn:NameAndSurnameOfAuditor>
<cmn:DescriptionOfAuditor contextRef="ctx-39" xml:lang="en">State Authorised Public Accountant </cmn:DescriptionOfAuditor>
<cmn:IdentificationNumberOfAuditor contextRef="ctx-39">mne24828</cmn:IdentificationNumberOfAuditor>
<gsd:NameOfSubmittingEnterprise contextRef="ctx-1" xml:lang="en">BioPorto A/S </gsd:NameOfSubmittingEnterprise>
<gsd:NameOfReportingEntity contextRef="ctx-1" xml:lang="en">BioPorto A/S </gsd:NameOfReportingEntity>
<gsd:AddressOfReportingEntityCountryIdentificationCode contextRef="ctx-1">DK</gsd:AddressOfReportingEntityCountryIdentificationCode>
<gsd:AddressOfReportingEntityPostCodeIdentifier contextRef="ctx-1" xml:lang="en">2900</gsd:AddressOfReportingEntityPostCodeIdentifier>
<gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="ctx-1" xml:lang="en">2900</gsd:AddressOfSubmittingEnterprisePostcodeAndTown>
<gsd:AddressOfReportingEntityCountry contextRef="ctx-1" xml:lang="en">Denmark </gsd:AddressOfReportingEntityCountry>
<gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx-1">17500317</gsd:IdentificationNumberCvrOfReportingEntity>
<gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="ctx-1">17500317</gsd:IdentificationNumberCvrOfSubmittingEnterprise>
<gsd:InformationOnTypeOfSubmittedReport contextRef="ctx-1">Annual report</gsd:InformationOnTypeOfSubmittedReport>
<cmn:TypeOfAuditorAssistance contextRef="ctx-1">Auditor's report on audited financial statements</cmn:TypeOfAuditorAssistance>
<gsd:ToolForPreparingTheXBRLInstanceDocument contextRef="ctx-1" xml:lang="en">ParsePort XBRL Converter</gsd:ToolForPreparingTheXBRLInstanceDocument>
<gsd:ReportingPeriodStartDate contextRef="ctx-1">2023-01-01</gsd:ReportingPeriodStartDate>
<gsd:ReportingPeriodEndDate contextRef="ctx-1">2023-12-31</gsd:ReportingPeriodEndDate>
<gsd:PrecedingReportingPeriodStartDate contextRef="ctx-1">2022-01-01</gsd:PrecedingReportingPeriodStartDate>
<gsd:PredingReportingPeriodEndDate contextRef="ctx-1">2022-12-31</gsd:PredingReportingPeriodEndDate>
<gsd:LegalEntityIdentifierOfReportingEntity contextRef="ctx-1">5299004SWFL5JAN4W830</gsd:LegalEntityIdentifierOfReportingEntity>
<arr:TypeOfModifiedOpinionOnAuditedFinancialStatements contextRef="ctx-1">Opinion</arr:TypeOfModifiedOpinionOnAuditedFinancialStatements>
<arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements contextRef="ctx-1">Basis for Opinion</arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements>
</xbrli:xbrl>